Additionally, LINC00330 in the ESCC TME can also inhibit the formation of CCL2-mediated M2 TAMs, promoting the reprogramming of ESCC TAMs into anticancer M1 TAMs and further reducing the malignancy of ESCC. Here, LINC00330 is linked to esophageal squamous cell carcinoma.